[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[S. 2408 Introduced in Senate (IS)]
<DOC>
118th CONGRESS
1st Session
S. 2408
To amend title XVIII of the Social Security Act to provide for patient-
focused listening sessions to improve prescription drug plan
transparency, access, and choice.
_______________________________________________________________________
IN THE SENATE OF THE UNITED STATES
July 20, 2023
Mr. Scott of South Carolina (for himself and Mr. Warner) introduced the
following bill; which was read twice and referred to the Committee on
Finance
_______________________________________________________________________
A BILL
To amend title XVIII of the Social Security Act to provide for patient-
focused listening sessions to improve prescription drug plan
transparency, access, and choice.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ``Initiating Meaningful Patient Review
Of Various Existing Part D Regulations Act'' or the ``IMPROVE Part D
Regulations Act''.
SEC. 2. PATIENT-FOCUSED LISTENING SESSIONS TO IMPROVE PRESCRIPTION DRUG
PLAN TRANSPARENCY, ACCESS, AND CHOICE.
Section 1860D-42 of the Social Security Act (42 U.S.C. 1395w-152)
is amended by adding at the end the following new subsection:
``(e) Patient-Focused Listening Sessions for Program
Improvements.--
``(1) In general.--No later than December 31, 2024, the
Secretary shall convene at least one patient-focused listening
session on potential administrative improvements to this part,
as described in paragraph (2).
``(2) Patient-focused listening sessions.--Any patient-
focused listening sessions convened under paragraph (1) shall
be open to the public and may include patients, beneficiaries,
caregivers, consumer and patient advocacy organizations, health
care providers, and other interested parties, as determined
appropriate by the Secretary. Such listening sessions may
include discussions of, and recommendations for program
improvements related to--
``(A) prescription drug plan disclosures and
comparative information made available to
beneficiaries;
``(B) tools and mechanisms to assist beneficiaries
in navigating plan complaint systems, as well as the
efficiency and effectiveness of such systems;
``(C) tools and mechanisms to assist beneficiaries
in selecting a prescription drug plan;
``(D) tools and mechanisms to assist beneficiaries
in navigating utilization management requirements, such
as step therapy and prior authorization;
``(E) access to, and effectiveness and utilization
of, electronic real-time benefit tools (as described in
section 1860D-4(o)) and beneficiary real-time benefit
tools (as described in section 423.128(d)(4) of title
42, Code of Federal Regulations, or any successor
regulation);
``(F) formulary management and oversight; and
``(G) other subjects relevant to patients and other
interested parties.
``(3) Program review.--Based on the recommendations
discussed during any patient-focused listening sessions
convened under paragraph (1), the Secretary shall conduct a
review of relevant regulatory and sub-regulatory requirements
under this part and shall consider, as appropriate, potential
regulatory or sub-regulatory changes to address issues raised
during such sessions.''.
<all>